{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,21]],"date-time":"2026-08-21T12:21:44Z","timestamp":1787314904945,"version":"build-2736575974"},"reference-count":34,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,2,13]],"date-time":"2026-02-13T00:00:00Z","timestamp":1770940800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,3,12]],"date-time":"2026-03-12T00:00:00Z","timestamp":1773273600000},"content-version":"vor","delay-in-days":27,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"DOI":"10.1038\/s41598-026-40034-3","type":"journal-article","created":{"date-parts":[[2026,2,13]],"date-time":"2026-02-13T06:15:11Z","timestamp":1770963311000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["NTM-host matched infection models for the classification of drug efficacy against rapid and slow growing nontuberculous mycobacteria species"],"prefix":"10.1038","volume":"16","author":[{"given":"Vincent E.","family":"Guglielmi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jason E.","family":"Cummings","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicholas J.","family":"Whittel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Erik A.","family":"Langland","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Richard A.","family":"Slayden","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,2,13]]},"reference":[{"issue":"2","key":"40034_CR1","doi-asserted-by":"publisher","first-page":"e0007083","DOI":"10.1371\/journal.pntd.0007083","volume":"13","author":"SL Baldwin","year":"2019","unstructured":"Baldwin, S. L., Larsen, S. E., Ordway, D., Cassell, G. & Coler, R. N. The complexities and challenges of preventing and treating nontuberculous mycobacterial diseases. PLoS Negl. Trop. Dis. 13 (2), e0007083 (2019).","journal-title":"PLoS Negl. Trop. Dis."},{"issue":"1","key":"40034_CR2","doi-asserted-by":"publisher","first-page":"74","DOI":"10.1186\/s12929-020-00667-6","volume":"27","author":"R Gopalaswamy","year":"2020","unstructured":"Gopalaswamy, R., Shanmugam, S., Mondal, R. & Subbian, S. Of tuberculosis and non-tuberculous mycobacterial infections\u2014a comparative analysis of epidemiology, diagnosis and treatment. J. Biomed. Sci. 27 (1), 74 (2020).","journal-title":"J. Biomed. Sci."},{"key":"40034_CR3","doi-asserted-by":"crossref","unstructured":"Dartois, V. & Dick, T. Drug development challenges in nontuberculous mycobacterial lung disease: TB to the rescue. J. Exp. Med. 219(6). (2022).","DOI":"10.1084\/jem.20220445"},{"key":"40034_CR4","doi-asserted-by":"publisher","first-page":"1394220","DOI":"10.3389\/fmicb.2024.1394220","volume":"15","author":"LE Conyers","year":"2024","unstructured":"Conyers, L. E. & Saunders, B. M. Treatment for non-tuberculous mycobacteria: challenges and prospects. Front. Microbiol. 15, 1394220 (2024).","journal-title":"Front. Microbiol."},{"issue":"4","key":"40034_CR5","doi-asserted-by":"publisher","first-page":"287","DOI":"10.1080\/17476348.2025.2479615","volume":"19","author":"A Lemson","year":"2025","unstructured":"Lemson, A. et al. Treatment of nontuberculous mycobacterial pulmonary disease requires a Stepwise and multidisciplinary approach. Expert Rev. Respir Med. 19 (4), 287\u2013299 (2025).","journal-title":"Expert Rev. Respir Med."},{"issue":"1","key":"40034_CR6","doi-asserted-by":"publisher","first-page":"462","DOI":"10.1186\/s12866-025-04196-w","volume":"25","author":"JE Cummings","year":"2025","unstructured":"Cummings, J. E. et al. Establishing translational performance standards for TB therapy using rifampicin-based regimens in a male and female high-burden murine model. BMC Microbiol. 25 (1), 462 (2025).","journal-title":"BMC Microbiol."},{"key":"40034_CR7","doi-asserted-by":"publisher","first-page":"1667592","DOI":"10.3389\/fphar.2025.1667592","volume":"16","author":"JE Cummings","year":"2025","unstructured":"Cummings, J. E. et al. Evaluating the efficacy of HRZE-based regimens in a high-burden murine model: a back-translational assessment of rifamycins and Moxifloxacin substitutions in tuberculosis treatment. Front. Pharmacol. 16, 1667592 (2025).","journal-title":"Front. Pharmacol."},{"issue":"1","key":"40034_CR8","doi-asserted-by":"publisher","first-page":"3690","DOI":"10.1038\/s41598-020-60452-1","volume":"10","author":"EC Maggioncalda","year":"2020","unstructured":"Maggioncalda, E. C. et al. A mouse model of pulmonary mycobacteroides abscessus infection. Sci. Rep. 10 (1), 3690 (2020).","journal-title":"Sci. Rep."},{"key":"40034_CR9","doi-asserted-by":"crossref","unstructured":"Pearce, C. M. et al. Mycobacterium abscessus pulmonary infection and associated respiratory function in cystic fibrosis-like betaenac mice. Front. Tuberc. 2. (2024).","DOI":"10.3389\/ftubr.2024.1473341"},{"key":"40034_CR10","unstructured":"Alshiraihi, I. M. et al. Characterization of new mouse models of acute and chronic Mycobacterium abscessus infection for antimicrobial drug screening. Antimicrob. Agents Chemother. e0047525 (2025)."},{"key":"40034_CR11","doi-asserted-by":"publisher","first-page":"102503","DOI":"10.1016\/j.tube.2024.102503","volume":"147","author":"V Dartois","year":"2024","unstructured":"Dartois, V. et al. Preclinical murine models for the testing of antimicrobials against Mycobacterium abscessus pulmonary infections: current practices and recommendations. Tuberculosis (Edinb). 147, 102503 (2024).","journal-title":"Tuberculosis (Edinb)"},{"issue":"2","key":"40034_CR12","first-page":"198","volume":"13","author":"S Aminabee","year":"2023","unstructured":"Aminabee, S. et al. Role of animal models in drug development: Past, present and future perspectives. Int. J. Res. Pharm. Chem. 13 (2), 198\u2013209 (2023).","journal-title":"Int. J. Res. Pharm. Chem."},{"key":"40034_CR13","doi-asserted-by":"publisher","first-page":"717","DOI":"10.3389\/fmicb.2017.00717","volume":"8","author":"L Zhan","year":"2017","unstructured":"Zhan, L., Tang, J., Sun, M. & Qin, C. Animal models for tuberculosis in translational and precision medicine. Front. Microbiol. 8, 717 (2017).","journal-title":"Front. Microbiol."},{"issue":"18","key":"40034_CR14","doi-asserted-by":"publisher","first-page":"e2423842122","DOI":"10.1073\/pnas.2423842122","volume":"122","author":"V Dartois","year":"2025","unstructured":"Dartois, V. et al. Next-generation rifamycins for the treatment of mycobacterial infections. Proc. Natl. Acad. Sci. U S A. 122 (18), e2423842122 (2025).","journal-title":"Proc. Natl. Acad. Sci. U S A"},{"issue":"4","key":"40034_CR15","doi-asserted-by":"publisher","first-page":"2129","DOI":"10.1128\/AAC.04841-14","volume":"59","author":"C Andrejak","year":"2015","unstructured":"Andrejak, C. et al. Characterization of mouse models of Mycobacterium avium complex infection and evaluation of drug combinations. Antimicrob. Agents Chemother. 59 (4), 2129\u20132135 (2015).","journal-title":"Antimicrob. Agents Chemother."},{"key":"40034_CR16","doi-asserted-by":"crossref","unstructured":"Sarathy, J. P. et al. TBAJ-876, a 3,5-Dialkoxypyridine analogue of Bedaquiline, is active against Mycobacterium abscessus. Antimicrob. Agents Chemother. 64 (4). (2020).","DOI":"10.1128\/AAC.02404-19"},{"key":"40034_CR17","doi-asserted-by":"crossref","unstructured":"Dick, T., Shin, S. J., Koh, W. J., Dartois, V. & Gengenbacher, M. Rifabutin is active against Mycobacterium abscessus in mice. Antimicrob. Agents Chemother. 64 (2). (2020).","DOI":"10.1128\/AAC.01943-19"},{"key":"40034_CR18","doi-asserted-by":"publisher","first-page":"1616149","DOI":"10.3389\/fmicb.2025.1616149","volume":"16","author":"A Lanni","year":"2025","unstructured":"Lanni, A., Iona, E., Fattorini, L., Giannoni, F. & Iacobino, A. Activity of combinations of bactericidal and bacteriostatic compounds in Mycobacterium abscessus-infected mice: an overview. Front. Microbiol. 16, 1616149 (2025).","journal-title":"Front. Microbiol."},{"issue":"2","key":"40034_CR19","doi-asserted-by":"publisher","first-page":"dlaf047","DOI":"10.1093\/jacamr\/dlaf047","volume":"7","author":"VL Nguyen","year":"2025","unstructured":"Nguyen, V. L. et al. Macrolide resistance in Mycobacterium abscessus: current insights and future perspectives. JAC Antimicrob. Resist. 7 (2), dlaf047 (2025).","journal-title":"JAC Antimicrob. Resist."},{"key":"40034_CR20","doi-asserted-by":"crossref","unstructured":"Hedges, L. V. J. Educational Behav. Stat. 6(2):107\u2013128. (1981).","DOI":"10.3102\/10769986006002107"},{"issue":"9","key":"40034_CR21","doi-asserted-by":"publisher","first-page":"917","DOI":"10.1093\/jpepsy\/jsp004","volume":"34","author":"JA Durlak","year":"2009","unstructured":"Durlak, J. A. How to select, calculate, and interpret effect sizes. J. Pediatr. Psychol. 34 (9), 917\u2013928 (2009).","journal-title":"J. Pediatr. Psychol."},{"issue":"3","key":"40034_CR22","doi-asserted-by":"publisher","first-page":"279","DOI":"10.4300\/JGME-D-12-00156.1","volume":"4","author":"GM Sullivan","year":"2012","unstructured":"Sullivan, G. M. & Feinn, R. Using effect Size-or why the P value is not enough. J. Grad Med. Educ. 4 (3), 279\u2013282 (2012).","journal-title":"J. Grad Med. Educ."},{"key":"40034_CR23","doi-asserted-by":"crossref","unstructured":"Cross, J., Gargate, N. & Rahman, K. M. Current advances in developing new antimicrobial agents against Non-Tuberculous Mycobacterium. Antibiot. (Basel).  14 (12). (2025).","DOI":"10.3390\/antibiotics14121189"},{"issue":"5","key":"40034_CR24","doi-asserted-by":"publisher","first-page":"381","DOI":"10.1038\/s41573-024-00897-5","volume":"23","author":"V Dartois","year":"2024","unstructured":"Dartois, V. & Dick, T. Therapeutic developments for tuberculosis and nontuberculous mycobacterial lung disease. Nat. Rev. Drug Discov. 23 (5), 381\u2013403 (2024).","journal-title":"Nat. Rev. Drug Discov"},{"issue":"7","key":"40034_CR25","doi-asserted-by":"publisher","first-page":"e3000410","DOI":"10.1371\/journal.pbio.3000410","volume":"18","author":"N Percie du Sert","year":"2020","unstructured":"Percie du Sert, N. et al. The ARRIVE guidelines 2.0: updated guidelines for reporting animal research. PLoS Biol. 18 (7), e3000410 (2020).","journal-title":"PLoS Biol."},{"key":"40034_CR26","doi-asserted-by":"publisher","first-page":"863","DOI":"10.3389\/fpsyg.2013.00863","volume":"4","author":"D Lakens","year":"2013","unstructured":"Lakens, D. Calculating and reporting effect sizes to facilitate cumulative science: a practical primer for t-tests and ANOVAs. Front. Psychol. 4, 863 (2013).","journal-title":"Front. Psychol."},{"issue":"4","key":"40034_CR27","doi-asserted-by":"publisher","first-page":"367","DOI":"10.1164\/rccm.200604-571ST","volume":"175","author":"DE Griffith","year":"2007","unstructured":"Griffith, D. E. et al. An official ATS\/IDSA statement: diagnosis, treatment, and prevention of nontuberculous mycobacterial diseases. Am. J. Respir Crit. Care Med. 175 (4), 367\u2013416 (2007).","journal-title":"Am. J. Respir Crit. Care Med."},{"issue":"3","key":"40034_CR28","doi-asserted-by":"publisher","first-page":"347","DOI":"10.1007\/s10096-013-1962-1","volume":"33","author":"HB Xu","year":"2014","unstructured":"Xu, H. B., Jiang, R. H. & Li, L. Treatment outcomes for Mycobacterium avium complex: a systematic review and meta-analysis. Eur. J. Clin. Microbiol. Infect. Dis. 33 (3), 347\u2013358 (2014).","journal-title":"Eur. J. Clin. Microbiol. Infect. Dis."},{"key":"40034_CR29","doi-asserted-by":"crossref","unstructured":"Rampacci, E., Stefanetti, V., Passamonti, F. & Henao-Tamayo, M. Preclinical models of nontuberculous mycobacteria infection for early drug discovery and vaccine research. Pathogens. 9 (8). (2020).","DOI":"10.3390\/pathogens9080641"},{"issue":"8","key":"40034_CR30","doi-asserted-by":"publisher","first-page":"1502","DOI":"10.1016\/j.drudis.2018.04.001","volume":"23","author":"ML Wu","year":"2018","unstructured":"Wu, M. L., Aziz, D. B., Dartois, V. & Dick, T. NTM drug discovery: status, gaps and the way forward. Drug Discov Today. 23 (8), 1502\u20131519 (2018).","journal-title":"Drug Discov Today"},{"issue":"10","key":"40034_CR31","doi-asserted-by":"publisher","first-page":"e1009965","DOI":"10.1371\/journal.ppat.1009965","volume":"17","author":"JR Sullivan","year":"2021","unstructured":"Sullivan, J. R. et al. Efficacy of Epetraborole against Mycobacterium abscessus is increased with Norvaline. PLoS Pathog. 17 (10), e1009965 (2021).","journal-title":"PLoS Pathog"},{"issue":"11","key":"40034_CR32","doi-asserted-by":"publisher","first-page":"6904","DOI":"10.1128\/AAC.00459-15","volume":"59","author":"A Obregon-Henao","year":"2015","unstructured":"Obregon-Henao, A. et al. Susceptibility of Mycobacterium abscessus to antimycobacterial drugs in preclinical models. Antimicrob. Agents Chemother. 59 (11), 6904\u20136912 (2015).","journal-title":"Antimicrob. Agents Chemother."},{"key":"40034_CR33","doi-asserted-by":"crossref","unstructured":"Pohl, K. et al. Mycobacterium abscessus clearance by neutrophils is independent of autophagy. Infect. Immun. 88 (8). (2020).","DOI":"10.1128\/IAI.00024-20"},{"issue":"9","key":"40034_CR34","doi-asserted-by":"publisher","first-page":"3554","DOI":"10.1172\/JCI46095","volume":"121","author":"M Renna","year":"2011","unstructured":"Renna, M. et al. Azithromycin blocks autophagy and May predispose cystic fibrosis patients to mycobacterial infection. J. Clin. Invest. 121 (9), 3554\u20133563 (2011).","journal-title":"J. Clin. Invest."}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-026-40034-3","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-026-40034-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-026-40034-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,12]],"date-time":"2026-03-12T09:20:57Z","timestamp":1773307257000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-026-40034-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2,13]]},"references-count":34,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["40034"],"URL":"https:\/\/doi.org\/10.1038\/s41598-026-40034-3","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,2,13]]},"assertion":[{"value":"5 November 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 February 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 February 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"All vertebrate animal use at Colorado State University was conducted in accordance with the Guide for the Care and Use of Laboratory Animals, 8th edition (National Academies Press, 2011), and approved by the Colorado State University Institutional Animal Care and Use Committee under protocol number 5172. The university is accredited by the Association for Assessment and Accreditation of Laboratory Animal Care International (AAALAC), and maintains an animal welfare assurance number A3572-01, which is on file with the NIH Office of Laboratory Animal Welfare (OLAW). Animals were housed in a state-of-the-art ABSL2 and ABSL3 facilities under the supervision of full-time staff veterinarians and support personnel. Veterinary care was provided in accordance with the American Veterinary Medical Association (AVMA) Guidelines.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval and consent to participate"}}],"article-number":"8762"}}